Back to Top Skip to main content

Brief Report: Diagnoses of Scarlet Fever in Military Health System (MHS) Beneficiaries Under 17 Years of Age Across the MHS and in England, 2013–2018

A maculopapular rash, a hallmark symptom of measles, on an infant’s face. Credit: CDC/Jim Goodson, M.P.H. A maculopapular rash, a hallmark symptom of measles, on an infant’s face. Credit: CDC/Jim Goodson, M.P.H.

Recommended Content:

Medical Surveillance Monthly Report

BACKGROUND

Scarlet fever is an illness caused by infection with Streptococcus pyogenes that most commonly occurs in childhood (peak age = 7–8 years old). It is characterized by an erythematous, sandpaper-like rash due to one of several erythrogenic exotoxins produced by group A streptococci. Scarlet fever typically occurs with streptococcal pharyngitis but may rarely develop with skin or wound infections. Aside from the widespread rash, scarlet fever has the same sequelae and treatment as streptococcal pharyngitis without a rash. Cases typically follow a seasonal pattern, more commonly arising in late fall, winter, and spring. S. pyogenes has over 240 distinct serotypes based on M-protein serotype and the more discriminating M-protein gene sequencing (known as emm types).1

Because scarlet fever is a reportable disease in England, a large increase in incident cases was identified in 2014. This increase has continued to persist throughout the country. Public health surveillance identified a 3- to 4-fold increase in incidence of scarlet fever, which has significantly impacted schools and nurseries in the country.2 Strains of S. pyogenes that were emm typed during this time period demonstrated a wide variety of M-protein gene sequences, but a new emm1 strain (M1UK) that is genotypically distinct from other pandemic emm1 isolates has increased in prevalence in England as invasive streptococcal disease has also risen.3,4 Although increased incidence of scarlet fever had been described in parts of Asia since 2008, England was the first European country to detect a sudden large-scale increase in cases, and this discovery has led to concern about similar widespread outbreaks occurring in other areas of the world.2

Scarlet fever is not a reportable disease in the U.S.,5 and military surveillance currently does not routinely perform M-protein gene sequencing on group A streptococcus isolates. However, diagnoses of scarlet fever can be identified throughout the Military Health System (MHS) using International Classification of Diseases, 9th and 10th Revision (ICD-9 and ICD-10, respectively) codes. The objectives of this brief report were to review scarlet fever incidence in the MHS among patients under 17 years of age and to identify any large spikes in annual cases at military treatment facilities, particularly at the bases located in England.

METHODS

The surveillance period was 1 January 2013 through 31 December 2018. The surveillance population consisted of beneficiaries of the MHS who were under 17 years of age at the time of the incident diagnosis. Diagnoses of scarlet fever were ascertained from the Defense Medical Surveillance System, which includes administrative records of all medical encounters of individuals who received care in fixed (i.e., not deployed or at sea) medical facilities in the MHS or in civilian facilities when care was reimbursed by the MHS (i.e., Purchased CareThe TRICARE Health Program is often referred to as purchased care. It is the services we “purchase” through the managed care support contracts.purchased care). For surveillance purposes, an incident case of scarlet fever was defined by a qualifying ICD-9 or ICD-10 diagnosis code (Table 1) in any diagnostic position of a record of a hospitalization or an outpatient medical encounter. The incidence date was considered the date of the first hospitalization or outpatient medical encounter that included a case-defining diagnosis. An individual could be counted as an incident case of scarlet fever only once during the surveillance period; any beneficiary with a diagnosis of scarlet fever before the surveillance period was excluded from the analysis. Counts of scarlet fever diagnoses and incidence rates were calculated for each year of the surveillance period. Incidence rates were calculated as incident scarlet fever diagnoses per 10,000 person-years (p-yrs) and were stratified by selected demographic characteristics. Denominators for incidence rate calculations were calculated by identifying the number of beneficiaries who had at least 1 medical encounter during each year of the surveillance period. Diagnoses and incidence rates were calculated for the entire MHS in the primary analysis.

A secondary analysis was designed to identify a possible increasing trend in scarlet fever diagnoses in MHS beneficiaries receiving care in England during the surveillance period. For this analysis, cases were restricted to those who received a scarlet fever diagnosis at a facility located in England as identified through the Defense Medical Information System Identifier.

RESULTS

During the 6-year surveillance period, a total of 7,080 MHS beneficiaries under age 17 received an incident diagnosis of scarlet fever; 85 incident cases of scarlet fever were identified in MHS beneficiaries receiving care in England. A slightly greater proportion of cases was diagnosed among male beneficiaries, while the vast majority of cases occurred in beneficiaries under age 10 (Table 2). Across all MHS beneficiaries, the greatest number of scarlet fever cases occurred in 2013 (n=1,366) and the lowest number of cases occurred in 2018 (n=871). In contrast, in MHS beneficiaries receiving care in England, the greatest number of scarlet fever cases occurred in 2015 (n=20) and the lowest number of cases in 2017 (n=7) (Figure).
Across the MHS as a whole, crude annual incidence rates of scarlet fever diagnoses were relatively stable from 2013 through 2016 and then declined throughout the remainder of the surveillance period. In contrast, crude annual incidence rates among MHS beneficiaries in England increased almost 80% from 2013 through 2015. Subsequently, crude incidence rates declined slightly in 2016 to 30.8 cases per 10,000 p-yrs before declining to their lowest rates during the period in 2017. Rates increased again in 2018 to 23.9 cases per 10,000 p-yrs (Figure).

EDITORIAL COMMENT

In 2014, England experienced a large and unexpected increase in cases of scarlet fever over the previous year, and the increase in cases continued unabated through 2018. Results of the current analysis suggest that a similar increase in cases was seen in MHS beneficiaries in England between 2013 and 2015 and again in 2018, although scarlet fever incidence rates across the entire MHS were relatively stable during the same period.

While this brief report demonstrates that MHS beneficiaries in England did have increased incidence of scarlet fever during a period while England was experiencing an outbreak, it is more difficult to interpret scarlet fever rates across the MHS. A comparison between rates in the entire MHS cohort and the MHS England cohort could be impacted by differential coding practices in England versus other locations in the MHS. Because scarlet fever is not a reportable illness in the U.S., physicians may be more likely to code a streptococcal illness (e.g., strep pharyngitis) and rash separately, rather than using a specific scarlet fever code. Future analyses of all streptococcal infection diagnoses could provide some clarification of this issue. In addition, it is likely that medical providers in England were aware of the ongoing outbreak there and thus more likely to detect and diagnose scarlet fever cases when they presented in American beneficiaries (i.e., detection bias).

Although the increase in incidence rates of scarlet fever in England is striking, it is important to recognize that the increase in the number of cases from year to year was relatively small. Only 85 cases were ascertained over 6 years among MHS beneficiaries in England, and the largest increase in the absolute number of cases was 6 cases from 2017–2018. When the numbers of cases used to compute rates are small, those rates can have poor reliability. This significant limitation should be considered when interpreting these data. Another limitation is that denominators used in the calculation of incidence rates were based on the number of beneficiaries who sought care at least once during the year rather than the number of beneficiaries eligible for care. Therefore, the denominator used for these calculations is likely an underestimate of the true denominator.

Fluctuations in crude annual rates of scarlet fever are likely due to a number of factors that include the number and emergence of new strep A strains, how widely those strains may be circulating, and the degree of immunity to those strains in a susceptible population. One possible reason for the increase in England has been attributed to a new emm1 strain of S. pyogenes,3 but it is unclear whether, and to what extent, this may have impacted rates of scarlet fever in MHS beneficiaries. Laboratory surveillance of this and other emerging strains in military populations may be warranted.
Wherever DoD personnel and their families are stationed, they are at risk from infectious outbreaks in the local community and/or country. This brief report provides an example of the importance of monitoring local public health reports to provide optimal medical care to active duty members and MHS beneficiaries.

Author affiliations: Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD (Maj Sayers); Defense Health Agency, Armed Forces Health Surveillance Branch (Mr. Bova, Dr. Clark).

REFERENCES

1.  Committee on Infectious Diseases, American Academy of Pediatrics. Red Book: 2018–2021 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
2.  Lamagni T, Guy R, Chand M, et al. Resurgence of scarlet fever in England, 2014–16: a population-based surveillance study. Lancet Infect Dis. 2018;18(2):180–187.
3.  Lynskey NN, Jauneikaite E, Li HK, et al. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect Dis. 2019;19(11):1209–1218.
4.  Brouwer S, Lacey JA, You Y, Davies MR, Walker MJ. Scarlet fever changes its spots. Lancet Infect Dis. 2019;19(11):1154–1155.
5.  Centers for Disease Control and Prevention. Group A streptococcal (GAS) disease. https://www.cdc.gov/groupastrep/surveillance.html. Accessed 24 September 2019.

Numbers of incident cases and crude incidence rates of scarlet fever, by location, MHS beneficiaries under 17 years of age, 2013–2018

ICD-9 and ICD-10 codes used to identify scarlet fever cases  

Counts and percentages of scarlet fever cases, by age and sex, all MHS beneficiaries and beneficiaries within England, 2013–2018

You also may be interested in...

Update: Heat Illness, Active Component, U.S. Armed Forces, 2019

Article
4/1/2020
Service members from Joint Task Force-Bravo participate in Chapel Hike 75. In spite of the heat, sun and exhaustion, service members were enthusiastically hiking the road mountain to provide food for the local community. (U.S. Army photo by Martin Chahin)

Recommended Content:

Medical Surveillance Monthly Report

Update: Exertional Rhabdomyolysis, Active Component, U.S. Armed Forces, 2015–2019

Article
4/1/2020
Midshipmen from the U.S Naval Academy Class of 2016 conduct a log carrying exercise. (U.S. Navy photo by Mass Communication Specialist 2nd Class Todd Frantom)

Update: Exertional Rhabdomyolysis, Active Component, U.S. Armed Forces, 2015–2019

Recommended Content:

Medical Surveillance Monthly Report

Commentary: The Warrior Heat- and Exertion-Related Event Collaborative and the Fort Benning Heat Center

Article
4/1/2020
A U.S. Navy Basic Underwater Demolition/SEAL student moves through the weaver during an obstacle course session in the first phase of training. (U.S. Navy photo by Mass Communication Specialist 2nd Class Kyle D. Gahlau/Released)

Recommended Content:

Medical Surveillance Monthly Report

Update: Sexually Transmitted Infections, Active Component, U.S. Armed Forces, 2011-2019

Article
3/1/2020
Photomicrograph of a Gram-stained specimen demonstrating the presence of Gram-negative, intracellular diplococci, which is a finding indicative of the possible presence of Neisseria gonorrhoeae bacteria. Credit: CDC/Bill Schwartz

Recommended Content:

Medical Surveillance Monthly Report

Incidence of Sexually Transmitted Infections Before and After Insertion of an Intrauterine Device or Contraceptive Implant, Active Component Service Women, U.S. Armed Forces, 2014–2019

Article
3/1/2020
A copper intrauterine device.

Recommended Content:

Medical Surveillance Monthly Report

Blood Lead Level Surveillance Among Pediatric Beneficiaries in the Military Health System, 2010–2017

Article
3/1/2020
U.S. Air Force Staff Sgt. Katie Duff, a medical technician with the 193rd Special Operations Wing's Medical Group, pricks the finger of brave 23-month old Kahia Inman, while his mother Malia Duvauchelle holds him during a free health screening. (U.S. Air Force photo by Tech. Sgt. Culeen Shaffer)

Recommended Content:

Medical Surveillance Monthly Report

Diabetes Mellitus and Gestational Diabetes, Active and Reserve Component Service Members and Dependents, 2008–2018

Article
2/1/2020
Master Sgt. Tara Taylor performs a glucose checks wile a young girl consoles her mother. (U.S. Air National Guard photo by Staff Sgt. Bethany Rizor)

Recommended Content:

Medical Surveillance Monthly Report

Increased Risk for Stress Fractures and Delayed Healing with NSAID Receipt, U.S. Armed Forces, 2014–2018

Article
2/1/2020
Credit: iStock

Recommended Content:

Medical Surveillance Monthly Report

Update: Malaria, U.S. Armed Forces, 2019

Article
2/1/2020
An Anopheles gambiae mosquito in the process of obtaining a blood meal. Credit: CDC/James D. Gathany

Recommended Content:

Medical Surveillance Monthly Report

Images in Health Surveillance: Skin Rashes in Children due to Infectious Causes

Article
2/1/2020
A maculopapular rash, a hallmark symptom of measles, on an infant’s face. Credit: CDC/Jim Goodson, M.P.H.

Recommended Content:

Medical Surveillance Monthly Report

Respiratory Pathogen Surveillance Trends and Influenza Vaccine Effectiveness Estimates for the 2018–2019 Season Among Department of Defense Beneficiaries

Article
1/6/2020
Navy Seaman Kenny Liu prepares a needle with a flu vaccination aboard the USS Gerald R. Ford in Newport News, Va., Oct. 22, 2019. The ship’s crew received flu vaccines.

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Prevalence of Idiopathic Corneal Ectasias, Active Component, 2001–2018

Article
1/6/2020
Keratoconus. Credit: © 2019 American Academy of Ophthalmology.

Recommended Content:

Medical Surveillance Monthly Report

Carbon Monoxide Poisoning, Active and Reserve Component Service Members and Non-Service Member Beneficiaries of the Military Health System, U.S. Armed Forces, July 2009–June 2019

Article
1/6/2020
Combustion fumes from a car exhaust pipe. (iStock photo).

Recommended Content:

Medical Surveillance Monthly Report

Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency, U.S. Armed Forces, May 2004–September 2018

Article
12/1/2019
Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt)

Recommended Content:

Medical Surveillance Monthly Report

Case Report: Hansen’s Disease in an Active Duty Soldier Presenting with Type 1 Reversal Reaction

Article
12/1/2019
Ulcer along the interspace between the patient’s right index and middle fingers. Photograph courtesy of Brooke Army Medical Center Medical Photography.

Recommended Content:

Medical Surveillance Monthly Report
<< < 1 2 3 4 5  ... > >> 
Showing results 16 - 30 Page 2 of 11

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.